CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

CorMedix shares have jumped 41.4% YTD, outpacing the industry as commercial adoption of FDA‑approved DefenCath (taurolidine+heparin) — launched in 2024 and patent‑protected through 2033 — generated $167.6m in net sales in the first nine months of 2025. The company closed a $300m acquisition of Melinta in August 2025, adding seven approved hospital/infectious‑disease products that contributed $12.8m in Q3 and potential upside from Rezzayo’s prophylaxis program (top‑line data due Q2 2026; TAM >$2bn), prompting management to raise pro forma 2025 net revenue guidance to $390–$410m. Analysts have materially boosted EPS estimates (2025 from $1.85 to $2.87; 2026 from $2.49 to $2.88) and the stock trades at a trailing P/B of 2.40 versus the industry’s 3.51, but risks persist from large incumbents (Pfizer, Amphastar, Baxter, Fresenius, B. Braun) and a limited internal pipeline; Zacks assigns a #1 (Strong Buy) rating.

Analysis

CorMedix shares have rallied 41.4% year-to-date, driven by rapid commercial adoption of DefenCath, the FDA-approved taurolidine+heparin catheter lock launched in 2024; management reports $167.6 million in net sales for the first nine months of 2025 and patent protection through 2033, with higher-than-expected outpatient utilization and planned label expansion into total parenteral nutrition cited as near-term growth levers. The company completed a $300 million acquisition of Melinta Therapeutics in August 2025, adding seven approved hospital/infectious-disease products that contributed $12.8 million in Q3 2025 and created a potential upside via Rezzayo’s prophylaxis program, whose top-line data are expected in Q2 2026 against a management-estimated prophylaxis TAM of more than $2 billion. Management raised pro forma 2025 net revenue guidance to $390–$410 million from a prior floor of $375 million, and street EPS estimates have been revised materially higher (2025: $1.85 to $2.87; 2026: $2.49 to $2.88), supporting a moderately positive market view. Valuation remains below peers on trailing price/book (2.40 vs industry 3.51) but risks include a limited internal pipeline and the potential for well-capitalized incumbents (Pfizer, Amphastar, Baxter, Fresenius, B. Braun) to enter CRBSI prevention and pressure CorMedix’s first-mover position.

Key Decisions for Investors

• Consider adding to positions on continued DefenCath momentum and improved 2025 guidance given the attractive P/B relative to the industry, while sizing exposure to company-specific execution risk
• Monitor near-term catalysts closely: quarterly DefenCath sales cadence, outpatient utilization trends, integration progress and sales ramp from the Melinta portfolio, and the Rezzayo prophylaxis top-line readout in Q2 2026
• Implement downside protection or limit position size to account for competitive risk from large incumbents capable of entering the catheter-related infection prevention market
• Reassess conviction if management fails to sustain revenue cadence, if Rezzayo data disappoints, or if competitive entrants materially target CRBSI indications